University of Lille
Also known as: Berkhout, Christophe | Centre Hospitalier Regional et Universitaire de Lille | Centre Oscar Lambret | Centre oscar Lambret de Lille | Centre Oscar Lambret - France | Centre Oscar Lambret_Lille | Centre Oscar Lambret-LILLE | Centre Oscar Lambret, Lille, France | Christophe Berkhout | CHR Lille | CHRU de Lille | CHRU Lille | CHRU, Lille | CHRU LILLE | CHU de Lille | CHU Lille | CHU LILLE | CIC, University Hospital, Lille | Department of Neurology, University Hospital, Lille | GHICL | Head of Lille Memory Clinic, CHRU Lille | Hopital Cardiologique, CHR de Lille, France | Hôpital Roger Salengro CHRU de Lille | Lille CU | Lille (FR), Oscar Lambret Center | Lille University | Lille University Hospital | Lille University Hospital, France | Lille Univ. UDSL | Oscar Lambret Center | SCALab UMR CNRS 9193 Université de Lille | Service des maladies du sang, CHRU de Lille | UH Lille | Université de Lille | University Hospital, Lille | University Hospital, Lille (France) | University Hospital Lille, Inserm, Univ Lille | University hospital of Lille | University Hospital of Lille | University Hospital of Lille (CHU Lille), France | University of Lille, CHU of Lille, France | University of Lille Nord de France | Univ Hosp of Lille, France
Highest phase reached
Phase 4
First clinical trial
Jul 1, 1996Last known activity
Nov 30, 2025
Timeline
1550s
- Jan 1, 1559
University of Lille— Founded
Drugs by trial phase (222 distinct, 204 trials)
Phase 4 (28 own, 0 via acquisition)
Phase 3 (80 own, 0 via acquisition)
Phase 2 (72 own, 0 via acquisition)
Phase 1 (11 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Adenocarcinoma
- Alcohol Drinking
- Alcoholism
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- Anorexia
- Anorexia Nervosa
- Anxiety Disorders
- Arthritis
- Arthritis, Rheumatoid
- Ascites
- Astrocytoma
- Atrial Fibrillation
- Basal Cell Carcinoma
- Blood Coagulation Disorders
- Blood Loss, Surgical
- Brain Neoplasms
- Breast Neoplasms
- Brugada Syndrome
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Central Nervous System Neoplasms
- Cerebral Hemorrhage
- Chondrocalcinosis
- Chronic Disease
- Chronic Pain
- Cognitive Dysfunction
- Colorectal Neoplasms
- Congenital Abnormalities
- Coronary Artery Disease
- Critical Illness
- Crohn Disease
- Cystic Fibrosis
- Dementia
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Disease Progression
- Earache
- Emergencies
- Endometrial Neoplasms
- Epilepsy
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Fever
- Fibrosis
- Folliculitis
- Gait Disorders, Neurologic
- Ganglion Cysts
- Gastrointestinal Stromal Tumors
- Glioblastoma
- Glioma
- Graft vs Host Disease
- Head and Neck Neoplasms
- Hemangiosarcoma
- Hematoma
- Hemorrhage
- Hemostatic Disorders
- Hepatitis
- Hepatitis A
- Hepatitis, Alcoholic
- Hypoglycemia
- Immunologic Deficiency Syndromes
- Infarction
- Infections
- Invasive Fungal Infections
- Iron Overload
- Joint Diseases
- Laryngeal Diseases
- Laryngeal Neoplasms
- Leukemia
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Promyelocytic, Acute
- Liver Diseases
- Liver Diseases, Alcoholic
- Lung Diseases
- Lung Diseases, Interstitial
- Lung Neoplasms
- Lupus Erythematosus, Systemic
- Lymphangioma
- Lymphatic Abnormalities
- Lymphoma
- Medulloblastoma
- Melanoma
- Meningeal Carcinomatosis
- Meningitis
- Mesothelioma
- Metabolic Diseases
- Motor Neuron Disease
- Multiple Myeloma
- Muscular Dystrophies
- Muscular Dystrophy, Oculopharyngeal
- Mycoses
- Myelodysplastic Syndromes
- Myocardial Infarction
Recent trials (50)
- NCT07273656Lead sponsorPhase 3Nov 30, 2025
- NCT06956482Lead sponsorPhase 3Oct 31, 2025
- NCT07214285Lead sponsorPhase 1/Phase 2Oct 1, 2025
- NCT07037043CollaboratorPhase 3Aug 31, 2025
- NCT07074002OfficialPhase 2Jul 31, 2025
- NCT06892951CollaboratorPhase 1/Phase 2Jun 30, 2025
- NCT06807164Lead sponsorPhase 2Feb 1, 2025
- NCT06807164OfficialPhase 2Feb 1, 2025
- NCT06734884Lead sponsorPhase 2Jan 6, 2025
- NCT06649227Lead sponsorPhase 1Jan 1, 2025
- NCT06649227OfficialPhase 1Jan 1, 2025
- NCT06658405Lead sponsorPhase 2Oct 31, 2024
- NCT06658405OfficialPhase 2Oct 31, 2024
- NCT06501807Lead sponsorN/ASep 2, 2024
- NCT06448572Lead sponsorPhase 1/Phase 2Jul 1, 2024
Details
- Founded
- Lille, FR Jan 1, 1559
- Last known activity
- Nov 30, 2025